Ventilator-associated pneumonia

Template:Ventilator-associated pneumonia Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.D. [2]

Natural History, Complications and Prognosis

Prognosis predictor scores: CURB-65 | Pneumonia severity index | Criteria for severe community acquired pneumonia

Diagnosis

Diagnostic criteria | History and Symptoms | Physical Examination | Laboratory Findings | Chest X Ray

Treatment

Medical Therapy Prevention

Prevention

Prevention of VAP involves limiting exposure to resistant bacteria, discontinuing mechanical ventilation as soon as possible, and a variety of strategies to limit infection while intubated. Resistant bacteria are spread in much the same ways as any communicable disease. Proper hand washing, sterile technique for invasive procedures, and isolation of individuals with known resistant organisms are all mandatory for effective infection control. A variety of aggressive weaning protocols to limit the amount of time a person spends intubation have been proposed. One important aspect is limiting the amount of sedation that a ventilated person receives.

Other recommendations for preventing VAP include raising the head of the bed to at least 45 degrees and placement of feedings tubes beyond the pylorus of the stomach. Antiseptic mouth washes such as chlorhexidine may also reduce the incidence of VAP. One study also suggests that using heat and moisture exchangers instead of heated humidifiers, may also reduce the incidence of VAP.

Epidemiology and prognosis

VAP occurs in up to 25% of all people who require mechanical ventilation. VAP can develop at any time during ventilation, but occurs more often in the first few days after intubation. This is because the intubation process itself contributes to the development of VAP. VAP occurring early after intubation typically involves fewer resistant organisms and is thus associated with a more favorable outcome. Because respiratory failure requiring mechanical ventilation is itself associated with a high mortality, determination of the exact contribution of VAP to mortality has been difficult. As of 2006, estimates range from 33% to 50% death in patients who develop VAP. Mortality is more likely when VAP is associated with certain microorganisms (Pseudomonas, Acinetobacter), blood stream infections, and ineffective initial antibiotics. VAP is especially common in people who have acute respiratory distress syndrome (ARDS).

See also

• Pneumonia
• Nosocomial infection

References

• American Thoracic Society and the Infectious Diseases Society of America. (2005). "ATS/IDSA Guidelines: Guidelines for the management of adults with HAP, VAP, and HCAP". Am J Respir Crit Care Med. 171: 388.

Template:WS